• Publications
  • Influence
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
TLDR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
TLDR
Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
TLDR
A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
TLDR
Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity.
Management of immune-related adverse events and kinetics of response with ipilimumab.
TLDR
A detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy are provided.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
TLDR
A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
TLDR
As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.
...
...